| Symbol | ORIC |
|---|---|
| Name | ORIC PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 240 E. GRAND AVENUE,2ND FLOOR, SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | +1 650 388-5600 |
| Fax | — |
| — | |
| Website | https://www.oricpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001796280 |
| Description | ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101, ORIC-944, ORIC-114, and ORIC-533. Additional info from NASDAQ: |
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
Read moreNew Form SCHEDULE 13G/A - Oric Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001738048-26-000058 <b>Size:</b> 17 KB
Read moreNew Form SCHEDULE 13G/A - Oric Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000919574-26-003469 <b>Size:</b> 11 KB
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
Read moreNew Form SCHEDULE 13G/A - Oric Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-12 <b>AccNo:</b> 0000078003-26-000067 <b>Size:</b> 8 KB
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
Read more(30% Negative) ORIC PHARMACEUTICALS, INC. (ORIC) Reports Q2 2026 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06816992 | ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exo… | Phase1 | Solid Tumors | Recruiting | 2025-02-27 | 2027-12-01 | ClinicalTrials.gov |
| NCT06012721 | Effect of Food on the Pharmacokinetics of ORIC-114 | Phase1 | Food Effect in Healthy Participants | Completed | 2023-09-11 | 2023-11-23 | ClinicalTrials.gov |
| NCT05413421 | Study of ORIC-944 in Patients With Metastatic Prostate Cancer | Phase1 | Metastatic Prostate Cancer | Recruiting | 2022-06-01 | 2026-09-01 | ClinicalTrials.gov |
| NCT05315700 | Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or H… | Phase1 | Solid Tumors | Recruiting | 2022-03-10 | 2027-09-01 | ClinicalTrials.gov |
| NCT05227144 | Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma | Phase1 | Relapsed or Refractory Multiple Myeloma | Completed | 2022-01-06 | 2025-03-03 | ClinicalTrials.gov |
| NCT04033328 | Study of ORIC-101 in Combination With Enzalutamide | Phase1 | Prostatic Neoplasms | Terminated | 2019-10-28 | 2023-12-04 | ClinicalTrials.gov |
| NCT03928314 | Study of ORIC-101 in Combination With Anticancer Therapy | Phase1 | Solid Tumor | Terminated | 2019-05-02 | 2023-12-04 | ClinicalTrials.gov |
| NCT03835637 | Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects | Phase1 | Healthy Volunteers | Completed | 2018-03-23 | 2018-07-04 | ClinicalTrials.gov |
| NCT03324555 | Study of ORIC-101 in Healthy Adult Subjects | Phase1 | Healthy Volunteers | Completed | 2017-10-19 | 2017-12-18 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets | Other | Phase PHASE1 | Metastatic Prostate Cancer | RECRUITING | NCT05413421 |
| Darolutamide (Nubeqa®) 300 mg tablets | Other | Phase PHASE1 | Metastatic Prostate Cancer | RECRUITING | NCT05413421 |
| Apalutamide (Erleada™) 60 mg or 240 mg tablets | Other | Phase PHASE1 | Metastatic Prostate Cancer | RECRUITING | NCT05413421 |
| Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets | Other | Phase PHASE1 | Metastatic Prostate Cancer | RECRUITING | NCT05413421 |
| ORIC-944 | Other | Phase PHASE1 | Metastatic Prostate Cancer | RECRUITING | NCT05413421 |
| ORIC-101 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03324555 |
| ORIC-101 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03835637 |
| enzalutamide 40 MG oral capsule [Xtandi] | Other | Phase PHASE1 | Prostatic Neoplasms | TERMINATED | NCT04033328 |
| ORIC-101 | Other | Phase PHASE1 | Prostatic Neoplasms | TERMINATED | NCT04033328 |
| Nab-paclitaxel | Other | Phase PHASE1 | Solid Tumor | TERMINATED | NCT03928314 |
| ORIC-101 | Other | Phase PHASE1 | Solid Tumor | TERMINATED | NCT03928314 |
| ORIC-114 | Other | Phase PHASE1 | Food Effect in Healthy Participants | COMPLETED | NCT06012721 |
| ORIC-533 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | COMPLETED | NCT05227144 |
| Chemotherapy drug | Drug | Phase PHASE1 | Solid Tumors | RECRUITING | NCT05315700 |
| ORIC-114 | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT05315700 |
| ORIC-114 Dose 3 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 2 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 1 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 3 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 2 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 1 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 3 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 2 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 1 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 3 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 2 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 1 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 3 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 2 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 1 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 3 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 2 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 1 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 3 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 2 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 1 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 3 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 2 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 1 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 3 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 2 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 1 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 3 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 2 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 1 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 3 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 2 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 1 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 3 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 2 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 1 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 3 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 2 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| ORIC-114 Dose 1 + amivantamab | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT06816992 |
| Placebo | DRUG | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT06080048 |
| SOR102 | DRUG | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT06080048 |